Trial Profile

Phase IB study of TNT009 in patients with Cold Agglutinin Disease

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Sep 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sutimlimab (Primary)
Indications Autoimmune haemolytic anaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

11 Dec 2017 According to a Bioverativ media release, primary and secondary outcome measures were achieved in the six patients with primary CAgD in the study.
11 Dec 2017 According to a Bioverativ media release, six primary CAgD patients data was presented at the 59th Annual Meeting of the American Hematology Society.
11 Dec 2017 Results (n=6) presented in a Bioverativ media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com